Defining Innovation: UK's NICE Responds To Recent Criticism Over Its Methods
This article was originally published in The Pink Sheet Daily
Executive Summary
The watchdog will discuss its proposals at a regularly scheduling public meeting on Sept. 16.
You may also be interested in...
Amgen's Prolia Bags Favorable Draft Appraisal From UK Medicines Watchdog
NICE considers denosumab a cost-effective use of NHS resources for second-line osteoporosis use.
Amgen's Prolia Bags Favorable Draft Appraisal From UK Medicines Watchdog
NICE considers denosumab a cost-effective use of NHS resources for second-line osteoporosis use.
NICE Rejects Vidaza, But Celgene Plans Comparator-Based Appeal
Cancer drug is effective but still too expensive even with a 7 percent price cut, NICE concludes.